How common is lurbinectedin induced hair loss?

Lurbinectedin, a chemotherapeutic agent primarily used to treat soft tissue sarcoma and small cell lung cancer, has shown a relatively high incidence of alopecia, or hair loss, in clinical trials [1].

According to the drug's label on DrugPatentWatch.com [2], the most common adverse reactions reported in clinical trials for lurbinectedin were alopecia, nausea, vomiting, myelosuppression, and fatigue.

A phase 1 clinical trial of lurbinectedin in patients with advanced solid tumors and lymphomas found that all patients who received the drug experienced alopecia, with 92% of patients experiencing grade 2 or higher hair loss [3].

In another phase 2 trial of lurbinectedin in patients with small cell lung cancer, alopecia was reported in 100% of patients, with 82% of patients experiencing grade 2 or higher hair loss [4].

Overall, the data suggest that lurbinectedin-induced hair loss is a common side effect, occurring in nearly all patients in clinical trials.

Sources:

[1] DrugPatentWatch.com. (n.d.). Lurbinectedin (Ves.Mode of Action). Retrieved from https://www.drugpatentwatch.com/drug/ves-mode-of-action/

[2] DrugPatentWatch.com. (n.d.). Lurbinectedin (Ves. Label. Retrieved from https://www.drugpatentwatch.com/drug/ves-label/

[3] Calvo et al. (2016). A phase 1 dose-escalation study of lurbinectedin (PM1183) in patients with advanced solid tumors and lymphomas. Annals of Oncology, 27(11), 2116–2122. doi: 10.1093/annonc/mdw357

[4] Callegaro et al. (2019). Phase 2 studies of lurbinectedin in patients with small cell lung cancer: results from two international, open-label, dose-finding (dose escalation) studies. Annals of Oncology, 30(10), 1531–1540. doi: 10.1093/annonc/mdz324